Feb 24, 2015
Ebola drug developed in Japan 'halved mortality rates' in some Guinea patients
A relatively cheap drug from a subsidiary of Fujifilm being tested against Ebola in Guinea has halved mortality rates in some patients.
Ebola drug developed in Japan 'halved mortality rates' in some Guinea patients
A relatively cheap drug from a subsidiary of Fujifilm being tested against Ebola in Guinea has halved mortality rates in some patients.
France says results of trials in Guinea of anti-Ebola drug encouraging
France said on Wednesday the first trials of a drug to treat Ebola in Guinea had been encouraging and appeared to accelerate the recovery process of patients, President Francois Hollande's office said in a statement. Trials of an experimental Japanese drug — Avigan, or favipiravir ...
Superbug spread through contaminated endoscopes sickened dozens in Seattle
A drug-resistant superbug infected 32 people at a Seattle hospital over a two-year period, with the bacteria spreading through contaminated medical scopes that had been cleaned to the manufacturer's recommendation, officials said on Thursday. Eleven of the patients infected at Virginia Mason Medical Center between ...
The two rooms of "The Collection 2015" offer two different kinds of collections. Room 1 displays the "Fujifilm Photo Collection," a special show to celebrate Fuji-film Co.'s 80th anniversary last year, and is composed of images taken by 101 renowned Japanese photographers. Room 2, however, commemorates ...
Avigan could be formally approved as Ebola drug early next year: Fujifilm
Fujifilm Holdings Corp. said Tuesday it expects its Avigan flu drug to be formally approved by early next year for treating patients infected with the Ebola virus. A clinical test of the drug, which the firm says has helped cure four Ebola patients in Europe, ...
Fujifilm to buy U.S. vaccine maker to expand biopharmaceutical business
Fujifilm Corp. said Monday it will acquire U.S. vaccine maker Kalon Biotherapeutics LLC to expand its biopharmaceutical business, with the Tokyo-based firm already having gained prominence for offering a possible treatment for Ebola patients. A Fujifilm subsidiary in the United States last Wednesday signed an ...
Flu drug aimed at Ebola may also fight norovirus, study finds
An experimental Japanese flu drug that has garnered headlines because of its potential to fight Ebola may also work against norovirus, the winter vomiting bug, British researchers said on Tuesday. As with Ebola, the research is still at an early stage but a study in ...
France, Guinea eye clinical tests of Japanese drug to treat Ebola
Fujifilm Corp. said Monday the French and Guinean governments are considering initiating clinical trials using the anti-influenza drug Favipiravir developed by its group firm Toyama Chemical Co. to treat patients infected with the Ebola virus. Fujifilm said it had been asked by France and Guinea ...
Fujifilm share jumps as Ebola patient given drug leaves hospital
Fujifilm Holdings Corp. shares rose to their highest level in more than six years in Tokyo trading Monday after a French Ebola patient, who was given its Avigan drug with another experimental treatment, was sent home from the hospital. The company's shares rose 2.8 percent ...
Fujifilm says French Ebola patient is taking its Avigan drug
A Fujifilm influenza medicine is being given to an Ebola patient at a French hospital, the latest treatment deployed in the global push to curtail the deadly virus.
Glaxo's Ebola vaccine may begin safety tests in humans next week
U.S. scientists will begin enrolling patients as soon as next week in clinical safety trials of GlaxoSmithKline PLC's experimental Ebola vaccine as the death toll from the disease rises in West Africa. The National Institutes of Health's Vaccine Research Center received approval from the Food ...
Japan to help fight Ebola outbreak if requested
If requested, the government will provide to the World Health Organization and other parties an unapproved medicine that might help combat the deadly Ebola virus, Chief Cabinet Secretary Yoshihide Suga says.